Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1993 1
1994 1
1995 1
1998 1
1999 1
2003 1
2005 2
2006 1
2007 1
2009 2
2010 3
2013 1
2014 3
2015 2
2016 3
2017 2
2018 1
2019 6
2020 3
2021 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, Lindqvist J, Farooqi A, Katheria A, Sauberan J, Singh J, Nelson K, Wickremasinghe A, Dong L, Hassinger DC, Aucott SW, Hayashi M, Heuchan AM, Carey WA, Derrick M, Fernandez E, Sankar M, Leone T, Perez J, Serize A; PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. Clyman RI, et al. J Pediatr. 2019 Feb;205:41-48.e6. doi: 10.1016/j.jpeds.2018.09.012. Epub 2018 Oct 16. J Pediatr. 2019. PMID: 30340932 Free PMC article. Clinical Trial.
OBJECTIVE: To compare early routine pharmacologic treatment of moderate-to-large patent ductus arteriosus (PDA) at the end of week 1 with a conservative approach that requires prespecified respiratory and hemodynamic criteria before treatment can be given. .. …
OBJECTIVE: To compare early routine pharmacologic treatment of moderate-to-large patent ductus arteriosus (PDA) at the …
Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320).
Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, Lindqvist J, Farooqi A, Katheria A, Sauberan J, Singh J, Nelson K, Wickremasinghe A, Dong L, Hassinger DC, Aucott SW, Hayashi M, Heuchan AM, Carey WA, Derrick M, Wolf IS, Kimball A, Sankar M, Leone T, Perez J, Serize A, Clyman RI. Liebowitz M, et al. J Perinatol. 2019 May;39(5):599-607. doi: 10.1038/s41372-019-0347-4. Epub 2019 Mar 8. J Perinatol. 2019. PMID: 30850756 Free PMC article. Clinical Trial.

OBJECTIVE: To evaluate the effectiveness of drugs used to constrict patent ductus arteriosus (PDA) in newborns < 28 weeks. METHODS: We performed a secondary analysis of the multi-center PDA-TOLERATE trial (NCT01958320). ...CONCLUSION: Indomethacin was more

OBJECTIVE: To evaluate the effectiveness of drugs used to constrict patent ductus arteriosus (PDA) in newborns < 28

Left-to-right shunt lesions.
Driscoll DJ. Driscoll DJ. Pediatr Clin North Am. 1999 Apr;46(2):355-68, x. doi: 10.1016/s0031-3955(05)70123-1. Pediatr Clin North Am. 1999. PMID: 10218080 Review.
This article discusses: the incidence, types, embryology, clinical presentations, physical examinations, electrocardiographic features, chest radiographs, echocardiographic and cardiac catheterization issues, treatment, natural history of atrial septal defects, and outcomes of tr …
This article discusses: the incidence, types, embryology, clinical presentations, physical examinations, electrocardiographic features, ches …
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Boghossian NS, Do BT, Bell EF, Dagle JM, Brumbaugh JE, Stoll BJ, Vohr BR, Das A, Shankaran S, Sanchez PJ, Wyckoff MH, Bethany Ball M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Boghossian NS, et al. Early Hum Dev. 2017 Oct;113:10-17. doi: 10.1016/j.earlhumdev.2017.07.011. Epub 2017 Jul 8. Early Hum Dev. 2017. PMID: 28697406 Free PMC article. Clinical Trial.
BACKGROUND: Optimal management of the patent ductus arteriosus (PDA) in preterm infants remains controversial. ...
BACKGROUND: Optimal management of the patent ductus arteriosus (PDA) in preterm infants remains controversial. ...
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants.
ElHassan NO, Bird TM, King AJ, Ambadwar PB, Jaquiss RD, Kaiser JR, Robbins JM. ElHassan NO, et al. J Neonatal Perinatal Med. 2014 Jan 1;7(3):229-35. doi: 10.3233/NPM-14814015. J Neonatal Perinatal Med. 2014. PMID: 25322995
BACKGROUND: Patent ductus arteriosus (PDA) occurs in 70% of extremely low birth weight (ELBW, birth weight <1000 g) infants. Approximately 34% of ELBW infants with a PDA have spontaneous closure. Failure of the ductus arteriosus to close has …
BACKGROUND: Patent ductus arteriosus (PDA) occurs in 70% of extremely low birth weight (ELBW, birth weight <1000 g) …
Prolonged Tracheal Intubation and the Association Between Patent Ductus Arteriosus and Bronchopulmonary Dysplasia: A Secondary Analysis of the PDA-TOLERATE trial.
Clyman RI, Kaempf J, Liebowitz M, Erdeve O, Bulbul A, Håkansson S, Lindqvist J, Farooqi A, Katheria A, Sauberan J, Singh J, Nelson K, Wickremasinghe A, Dong L, Hassinger DC, Aucott SW, Hayashi M, Heuchan AM, Carey WA, Derrick M, Fernandez E, Sankar M, Leone T, Perez J, Serize A; PDA-TOLERATE Trial Investigators. Clyman RI, et al. J Pediatr. 2021 Feb;229:283-288.e2. doi: 10.1016/j.jpeds.2020.09.047. Epub 2020 Oct 28. J Pediatr. 2021. PMID: 32979387 Free PMC article. Clinical Trial.
In the PDA-TOLERATE trial, persistent (even for several weeks) moderate to large patent ductus arteriosus (PDA) was not associated with an increased risk of BPD when the infant required <10 days of intubation. ...
In the PDA-TOLERATE trial, persistent (even for several weeks) moderate to large patent ductus arteriosus (PDA) was not …
Path Toward Proactive Therapy for Patent Ductus Arteriosus.
Yamada S, Terzic A. Yamada S, et al. Clin Pharmacol Ther. 2019 Dec;106(6):1187-1190. doi: 10.1002/cpt.1583. Epub 2019 Aug 21. Clin Pharmacol Ther. 2019. PMID: 31433488 Free PMC article. No abstract available.
Unicuspid aortic valve in children: a systematic review spanning four decades.
Mookadam F, Thota VR, Lopez AM, Emani UR, Tajik AJ. Mookadam F, et al. J Heart Valve Dis. 2010 Nov;19(6):678-83. J Heart Valve Dis. 2010. PMID: 21214089 Review.
Associated anomalies included 22 cases (37%) of aortic coarctation, seven (12%) with ventricular septal defect (VSD), three (5%) with patent ductus arteriosus (PDA), and three (5%) with aortic aneurysm. ...
Associated anomalies included 22 cases (37%) of aortic coarctation, seven (12%) with ventricular septal defect (VSD), three (5%) with pat
Contraception Practices and Pregnancy Outcome in Patients after Fontan Operation.
Pundi KN, Pundi K, Johnson JN, Dearani JA, Bonnichsen CR, Phillips SD, Canobbio MC, Driscoll DJ, Cetta F. Pundi KN, et al. Congenit Heart Dis. 2016 Jan-Feb;11(1):63-70. doi: 10.1111/chd.12291. Epub 2015 Aug 4. Congenit Heart Dis. 2016. PMID: 26239864
There was 1 neonatal death because of prematurity and two children were born with congenital heart disease (one patent ductus arteriosus and one membranous ventricular septal defect). ...
There was 1 neonatal death because of prematurity and two children were born with congenital heart disease (one patent ductus
Left atrial volume in children without heart disease and in those with ventricular septal defect or patent ductus arteriosus or hypertrophic cardiomyopathy.
Taggart NW, Cetta F, O'Leary PW, Seward JB, Eidem BW. Taggart NW, et al. Am J Cardiol. 2010 Nov 15;106(10):1500-4. doi: 10.1016/j.amjcard.2010.07.015. Epub 2010 Sep 21. Am J Cardiol. 2010. PMID: 21059443
We retrospectively reviewed the echocardiograms from 3 pediatric cohorts: group N (n = 522), children with normal echocardiographic findings; group VSD/PDA (n = 71), children with ventricular septal defect (VSD; n = 50) or patent ductus arteriosus (PDA; n = 2 …
We retrospectively reviewed the echocardiograms from 3 pediatric cohorts: group N (n = 522), children with normal echocardiographic findings …
35 results